A5043456864- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Renal and Vascular Pathologies
- Urologic and reproductive health conditions
- Global Health Care Issues
- Urinary Bladder and Prostate Research
- Urinary and Genital Oncology Studies
- Kidney Stones and Urolithiasis Treatments
- Hernia repair and management
- Healthcare Policy and Management
- Genital Health and Disease
- Pelvic floor disorders treatments
- Radiation Dose and Imaging
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- Urological Disorders and Treatments
- Colorectal Cancer Surgical Treatments
- Pediatric Urology and Nephrology Studies
- Surgical Simulation and Training
- COVID-19 and healthcare impacts
- Advanced Causal Inference Techniques
- Minimally Invasive Surgical Techniques
Presbyterian Hospital
2021-2025
Weill Cornell Medicine
2021-2025
New York Hospital Queens
2021-2025
NewYork–Presbyterian Hospital
2021-2025
Cornell University
2019-2025
Northwestern University
2017-2019
Penn Presbyterian Medical Center
2019
This cross-sectional study of data from the Surveillance, Epidemiology and End Results database assesses temporal trends in use active surveillance watchful waiting vs definitive treatment men with low- favorable intermediate–risk prostate cancer US between 2010 2018.
Background An immune checkpoint inhibitor (ICI) backbone is a standard of care for frontline metastatic clear cell renal carcinoma, involving either ICI doublet or tyrosine kinase (TKI) with ICI. These phase 3 trials used sunitinib control arm. The optimal regimen uncertain. Objective To compare long-term responders these using extended follow-up data stratified by International Metastatic RCC Database Consortium risk group. Methods Phase trial (CheckMate 214, KEYNOTE-426, CheckMate 9ER, and...
Historically, robotic-assisted radical prostatectomy is accompanied by an inpatient hospital admission. The COVID-19 pandemic necessitated a transition to same-day discharge in some centers free up critically needed beds. This study aims compare complications, total health care costs, and patient satisfaction for vs prostatectomy.
This cohort study uses published clinical trial data to assess long-term survival of patients with metastatic urothelial carcinoma who are treated immune checkpoint inhibitors.
To assess trends in hospital price disclosures after the Centers for Medicare & Medicaid Services (CMS) Final Rule went into effect.
Introduction Approximately one million prostate biopsies are performed annually in the USA, and most using a transrectal approach under local anaesthesia. The risk of postbiopsy infection is increasing due to antibiotic resistance rectal flora. Single-centre studies suggest that clean, percutaneous transperineal biopsy may have lower infection. To date, there no high-level evidence comparing versus biopsy. We hypothesise anaesthesia has significantly infection, similar pain/discomfort levels...
Expert consensus recommends treatment of magnetic resonance imaging (MRI)-visible prostate cancer (PCa). Outcomes partial-gland ablation (PGA) for MRI-invisible PCa remain unknown.
Prior work assessing disparities in cancer outcomes has relied on regional socioeconomic metrics. These metrics average data across many individuals, resulting a loss of granularity and confounding with other factors.
Abstract Context In the United States (US) men who undergo vasectomy and/or reversal (vasovasotomy) are likely to pay out‐of‐pocket for these procedures. We characterized publicly disclosed pricing of both procedures with a focus on variability in self‐pay prices. Methods queried all US hospitals prices and vasovasotomy. assessed interhospital compared charging high (≥75th percentile) low (≤25th either procedure. also examined trends after 2022 Supreme Court decision that allowed individual...
You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation II (MP35)1 May 2024MP35-07 RACIAL DIFFERENCES IN BLADDER CANCER MORTALITY ADJUSTING FOR SOCIODEMOGRAPHIC DISPARITIES A STATEWIDE REGISTRY Mollie Goldman, Camilo Arenas-Gallo, Adithya Balasubramanian, Jack Millot, Xian Wu, Alec Zhu, Stephen Rhodes, Jason Brown, and Jonathan E. Shoag GoldmanMollie Goldman , Arenas-GalloCamilo Arenas-Gallo BalasubramanianAdithya Balasubramanian MillotJack Millot WuXian Wu ZhuAlec Zhu...
You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy II (MP52)1 May 2024MP52-12 ASSOCIATION BETWEEN AGE AND MAJOR COMPLICATIONS AFTER ROBOTIC ASSISTED RADICAL PROSTATECTOMY: A MULTI-INSTITUTIONAL SERIES Alec Zhu, Amy L. Tin, Andrew J. Vickers, Keith Kowalczyk, Behfar Ehdaie, Belen Mora, Sofia Gereta, and Jim C. Hu ZhuAlec Zhu , TinAmy Tin VickersAndrew Vickers KowalczykKeith Kowalczyk EhdaieBehfar Ehdaie MoraBelen Mora GeretaSofia Gereta HuJim View All Author...
You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation I (MP08)1 May 2024MP08-19 IMPACT OF IMMUNOTHERAPY IN METASTATIC BLADDER CANCER PATIENTS WITH AND WITHOUT VISCERAL METASTASES: A META-ANALYSIS RCTS Alec Zhu, Stephen P. Rhodes, Parwiz Abrahimi, Xian Wu, Camilo A. Gallo, Manish Kuchakulla, Gal Wald, Mary O. Strasser, Lina Posada, Adithya Balasubramanian, Leo Dreyfuss, and Jonathan E. Shoag ZhuAlec Zhu , RhodesStephen Rhodes AbrahimiParwiz Abrahimi WuXian Wu GalloCamilo...
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP14)1 May 2024MP14-06 IMPACT OF ABIRATERONE ON SEXUAL FUNCTION IN MEN WITH ADVANCED PROSTATE CANCER: A META-ANALYSIS RCTS Alec Zhu, Aaron Brant, Xian Wu, Camilo A. Gallo, Manish Kuchakulla, Adithya Balasubramanian, Lina Posada, Leo Dreyfuss, Mary O. Strasser, Tenny R. Zhang, Robert Fisch, Brandon M. Wahba, Gal Wald, and Jonathan E. Shoag ZhuAlec Zhu , BrantAaron Brant WuXian Wu GalloCamilo Gallo...